67 related articles for article (PubMed ID: 14576827)
1. Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint.
Marquez N; Chappell SC; Sansom OJ; Clarke AR; Court J; Errington RJ; Smith PJ
Oncogene; 2003 Oct; 22(48):7642-8. PubMed ID: 14576827
[TBL] [Abstract][Full Text] [Related]
2. A role for mismatch repair in control of DNA ploidy following DNA damage.
Strathdee G; Sansom OJ; Sim A; Clarke AR; Brown R
Oncogene; 2001 Apr; 20(15):1923-7. PubMed ID: 11313940
[TBL] [Abstract][Full Text] [Related]
3. The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase.
Franchitto A; Pichierri P; Piergentili R; Crescenzi M; Bignami M; Palitti F
Oncogene; 2003 Apr; 22(14):2110-20. PubMed ID: 12687013
[TBL] [Abstract][Full Text] [Related]
4. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
5. Non-tumor cells from an MSH2-null individual show altered cell cycle effects post-UVB.
Narine KA; Felton KE; Parker AA; Tron VA; Andrew SE
Oncol Rep; 2007 Dec; 18(6):1403-11. PubMed ID: 17982623
[TBL] [Abstract][Full Text] [Related]
6. Microtubule stress modifies intra-nuclear location of Msh2 in mouse embryonic fibroblasts.
Marquez N; Chappell SC; Sansom OJ; Clarke AR; Teesdale-Spittle P; Errington RJ; Smith PJ
Cell Cycle; 2004 May; 3(5):662-71. PubMed ID: 15044851
[TBL] [Abstract][Full Text] [Related]
7. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis.
Russo MT; De Luca G; Casorelli I; Degan P; Molatore S; Barone F; Mazzei F; Pannellini T; Musiani P; Bignami M
Cancer Res; 2009 May; 69(10):4372-9. PubMed ID: 19435918
[TBL] [Abstract][Full Text] [Related]
8. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
Sansom OJ; Toft NJ; Winton DJ; Clarke AR
Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 activates a G2-M cell cycle checkpoint following 6-thioguanine-induced DNA mismatch damage.
Yamane K; Schupp JE; Kinsella TJ
Cancer Res; 2007 Jul; 67(13):6286-92. PubMed ID: 17616687
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous and mutagen-induced loss of DNA mismatch repair in Msh2-heterozygous mammalian cells.
Borgdorff V; van Hees-Stuivenberg S; Meijers CM; de Wind N
Mutat Res; 2005 Jul; 574(1-2):50-7. PubMed ID: 15914206
[TBL] [Abstract][Full Text] [Related]
11. DNA mismatch repair proteins promote apoptosis and suppress tumorigenesis in response to UVB irradiation: an in vivo study.
Young LC; Thulien KJ; Campbell MR; Tron VA; Andrew SE
Carcinogenesis; 2004 Oct; 25(10):1821-7. PubMed ID: 15166087
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair deficiency stimulates N-ethyl-N-nitrosourea-induced mutagenesis and lymphomagenesis.
Claij N; van der Wal A; Dekker M; Jansen L; te Riele H
Cancer Res; 2003 May; 63(9):2062-6. PubMed ID: 12727820
[TBL] [Abstract][Full Text] [Related]
13. A combination of MSH2 DNA mismatch repair deficiency and expression of the SV40 large T antigen results in cisplatin resistance of mouse embryonic fibroblasts.
Yasin SL; Rainbow AJ
Int J Oncol; 2011 Sep; 39(3):719-26. PubMed ID: 21667017
[TBL] [Abstract][Full Text] [Related]
14. Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect.
Campbell MR; Wang Y; Andrew SE; Liu Y
Oncogene; 2006 Apr; 25(17):2531-6. PubMed ID: 16331258
[TBL] [Abstract][Full Text] [Related]
15. p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2.
Jackson MW; Agarwal MK; Yang J; Bruss P; Uchiumi T; Agarwal ML; Stark GR; Taylor WR
J Cell Sci; 2005 May; 118(Pt 9):1821-32. PubMed ID: 15827088
[TBL] [Abstract][Full Text] [Related]
16. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/- mice.
Krynetskaia NF; Brenner TL; Krynetski EY; Du W; Panetta JC; Ching-Hon P; Evans WE
Mol Pharmacol; 2003 Aug; 64(2):456-65. PubMed ID: 12869651
[TBL] [Abstract][Full Text] [Related]
17. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells.
Zhang X; Xu LS; Wang ZQ; Wang KS; Li N; Cheng ZH; Huang SZ; Wei DZ; Han ZG
FEBS Lett; 2004 Jul; 570(1-3):7-12. PubMed ID: 15251430
[TBL] [Abstract][Full Text] [Related]
18. DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting.
Ree AH; Stokke T; Bratland A; Patzke S; Nome RV; Folkvord S; Meza-Zepeda LA; Flatmark K; Fodstad O; Andersson Y
Anticancer Res; 2006; 26(3A):1909-16. PubMed ID: 16827124
[TBL] [Abstract][Full Text] [Related]
19. Senescence-dependent MutS alpha dysfunction attenuates mismatch repair.
Chang IY; Jin M; Yoon SP; Youn CK; Yoon Y; Moon SP; Hyun JW; Jun JY; You HJ
Mol Cancer Res; 2008 Jun; 6(6):978-89. PubMed ID: 18567801
[TBL] [Abstract][Full Text] [Related]
20. Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells.
Cheung HW; Jin DY; Ling MT; Wong YC; Wang Q; Tsao SW; Wang X
Cancer Res; 2005 Feb; 65(4):1450-8. PubMed ID: 15735033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
